NASDAQ:PSNL   Personalis, Inc.
Biotech has taken a beating to say the least!

There is a bullish divergence on RSI. Many draw bullish divergences using the price valleys and price peaks to draw a bearish divergence. Price made a lower low, forming the possible head, while RSI formed a higher low.

Possible Inverse head and shoulder, and if so, there appears to be a sloping neckline.

I do notice a tall volume spike during the formation of the head.

So far the support at the top of a prior small gap up has held. Support and resistance levels were made to be broken or securities would be ranging all of the time, but for now it has held. It amazes me sometimes how price can remember that little gap. I am not saying it will hold, but price remembered it.

Price did take a dip below the bollinger band with the moving average set on 80 verses 20, which shows heavy selling pressure. That is about the same time the large volume bar appeared. Price also was above the bollinger band when it made 2 of the peaks that formed the ugly top.

Short interest is surprisingly low. Negative volume is up there so smart money may still have their eye on this one.

The 200 daily moving average is still sloping upward. The 100 is a bit on the flat side and the 50 is sloping down right now and has crossed down and through the 100. Price is below the 50 which is bearish.

Watching and not a recommendation.

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.